Acrivon Therapeutics stockholders elect two Class I directors and ratify auditor

Acrivon Therapeutics, Inc.

Michael Tomsicek elected Class I director with 17,527,002 votes for and 226,168 withheld.
Charles Baum elected Class I director with 17,660,794 votes for and 91,113 withheld.
Ratification of PricewaterhouseCoopers as auditor for FY2023: 17,879,658 for, 725 against.
Quorum of 17,880,383 shares (81.55% of outstanding) present at the 2023 annual meeting.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Acrivon Therapeutics, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-06-22 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-22

Exact text from the filing

Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 by the following vote: For Against Abstain Broker Non-Votes 17,879,658 725 0 -

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Acrivon Therapeutics, Inc. shareholders approved Election of Class I Director at the 2023-06-22 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-22

Exact text from the filing

Proposal One: Election of Michael Tomsicek, M.B.A. as a Class I Director Michael Tomsicek was elected to serve as a Class I director to hold office until the Company’s 2026 Annual Meeting of Stockholders and until the election and qualification of his successor. Votes were cast as follows: For Withheld Broker Non-Votes Michael Tomsicek, M.B.A. 17,527,002 226,168 127,213

View on SEC.gov

Browse all shareholder votes →

Acrivon Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-029447

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.